We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Amazon, Thermo Fisher, Eli Lilly, Google and CVS Health
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 14, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Eli Lilly and Company (LLY - Free Report) , Alphabet Inc. (GOOGL - Free Report) and CVS Health Corporation (CVS - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Amazon, Thermo Fisher and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Thermo Fisher Scientific and Eli Lilly. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amazon shares have outperformed the S&P 500 over the past year (+66.9% vs. +17.6%). The Zacks analyst believes that Amazon is gaining on solid Prime momentum owing to ultrafast delivery services and strong content portfolio.
Further, a coronavirus-led spike in online orders continues to be a major tailwind. Also, solid growth in its online stores sales remains a positive. Moreover, the surge in online grocery shopping is another positive. Additionally, the strong adoption rate of AWS is aiding the company’s cloud dominance.
Moreover, expanding the AWS services portfolio is continuously helping Amazon in gaining further momentum among the customers. Further, improving Alexa skills and expanding smart home products portfolio are positives. However, accelerating coronavirus related expenses remain risks for the company’s margin expansion in the near term. Also, rising cloud competition poses risk.
Shares of Thermo Fisher have gained +28.7% in the last six months against the Zacks Medical Instruments industry’s gain of +18.1%. The Zacks analyst is optimistic about the exceptionally strong growth at Life Sciences Solutions and Specialty Diagnostics segments.
In terms of end market, pharma and biotech registered growth on robust performance in bioproduction and pharma services. In diagnostics and healthcare, the company experienced exceptionally high demand for COVID-19 testing. A strong capital structure looks encouraging.
The company’s third quarter results were better-than-expected. However, the coronavirus outbreak has massively disrupted the global supply chain. One of the end markets registered loss in the third quarter, largely due to customer shutdowns in China.
Eli Lilly’s shares have gained +20.5% over the past three months against the Zacks Large Cap Pharmaceuticals industry’s rise of +5.6%. The Zacks analyst believes that Lilly is making significant pipeline progress including its efforts to make therapies to treat COVID-19.
It is regularly adding promising new pipeline assets through business development deals. It expects revenue growth to be driven by higher demand for drugs like Trulicity, Taltz, and others.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds. Estimates have gone up ahead of Q4 results. Lilly has a positive record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include Alphabet and CVS Health.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights: Amazon, Thermo Fisher, Eli Lilly, Google and CVS Health
For Immediate Release
Chicago, IL – January 14, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (AMZN - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , Eli Lilly and Company (LLY - Free Report) , Alphabet Inc. (GOOGL - Free Report) and CVS Health Corporation (CVS - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Amazon, Thermo Fisher and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Thermo Fisher Scientific and Eli Lilly. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Amazon shares have outperformed the S&P 500 over the past year (+66.9% vs. +17.6%). The Zacks analyst believes that Amazon is gaining on solid Prime momentum owing to ultrafast delivery services and strong content portfolio.
Further, a coronavirus-led spike in online orders continues to be a major tailwind. Also, solid growth in its online stores sales remains a positive. Moreover, the surge in online grocery shopping is another positive. Additionally, the strong adoption rate of AWS is aiding the company’s cloud dominance.
Moreover, expanding the AWS services portfolio is continuously helping Amazon in gaining further momentum among the customers. Further, improving Alexa skills and expanding smart home products portfolio are positives. However, accelerating coronavirus related expenses remain risks for the company’s margin expansion in the near term. Also, rising cloud competition poses risk.
(You can read the full research report on Amazon here >>>)
Shares of Thermo Fisher have gained +28.7% in the last six months against the Zacks Medical Instruments industry’s gain of +18.1%. The Zacks analyst is optimistic about the exceptionally strong growth at Life Sciences Solutions and Specialty Diagnostics segments.
In terms of end market, pharma and biotech registered growth on robust performance in bioproduction and pharma services. In diagnostics and healthcare, the company experienced exceptionally high demand for COVID-19 testing. A strong capital structure looks encouraging.
The company’s third quarter results were better-than-expected. However, the coronavirus outbreak has massively disrupted the global supply chain. One of the end markets registered loss in the third quarter, largely due to customer shutdowns in China.
(You can read the full research report on Thermo Fisher here >>>)
Eli Lilly’s shares have gained +20.5% over the past three months against the Zacks Large Cap Pharmaceuticals industry’s rise of +5.6%. The Zacks analyst believes that Lilly is making significant pipeline progress including its efforts to make therapies to treat COVID-19.
It is regularly adding promising new pipeline assets through business development deals. It expects revenue growth to be driven by higher demand for drugs like Trulicity, Taltz, and others.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds. Estimates have gone up ahead of Q4 results. Lilly has a positive record of earnings surprises in the recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Other noteworthy reports we are featuring today include Alphabet and CVS Health.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.